AHARNA GUIN

Employment

• IISER Tirupati PDRF
  2025 - Present
• Bose Institute - Centenary Campus ICMR-Research Associate
  2018 - 2023
• Institute of Postgraduate Medical Education and Research ICMR-Senior Research Fellow
  2014 - 2017
• Institute of Postgraduate Medical Education and Research Junior Research Fellow - ICMR project
  2009 - 2012
• Bose Institute Project Assistant
  2009 - 2009

Education

• University of Calcutta Ph.D. in Biochemistry (Clinical Immunology)
  2009 - 2016
• University of Kalyani Masters in Molecular Biology and Biotechnology
  2006 - 2008
• University of Calcutta Bachelors in Microbiology (Honours)
  2003 - 2006
• Welland Gouldsmith School Class XII (ISC)
  2001 - 2003
• Welland Gouldsmith School, Kolkata, India Class X (ICSE)
  1989 - 2001

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Complementary Use of Resveratrol Improves Low-Grade Chronic Inflammation Unresolved by Standard DMARD Therapy in Rheumatoid Arthritis
  2026 DOI: 10.64898/2026.07.24.26358846
  +Save
• Data from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2025 DOI: 10.1158/2326-6066.c.6551210
  +Save
• Supplementary Figures from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2025 DOI: 10.1158/2326-6066.30720876
  +Save
• Supplementary Tables from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2025 DOI: 10.1158/2326-6066.30720873
  +Save
• Supplementary Tables from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2023 DOI: 10.1158/2326-6066.22546565.v1
  +Save
• Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  Cancer Immunology Research 2023 DOI: 10.1158/2326-6066.CIR-21-1073
  +Save
• Supplementary Tables from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2023 DOI: 10.1158/2326-6066.22546565
  +Save
• Supplementary Figures from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2023 DOI: 10.1158/2326-6066.22546568.v1
  +Save
• Supplementary Figures from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2023 DOI: 10.1158/2326-6066.22546568
  +Save
• Data from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2023 DOI: 10.1158/2326-6066.c.6551210.v1
  +Save